Supriya Lifescience Limited (NSE: SUPRIYA) and Symbiotec Pharmalab (NSE: SYMBIOTEC) are both listed in the Medicinal Chemicals and Botanical Products industry. Supriya Lifescience has a market capitalisation of ₹6,746 Cr and Symbiotec Pharmalab ₹7,871 Cr, as of 9 Nov 2026. Their P/E ratios are 32.3 and 64.5 respectively.
| Metric | Supriya Lifescience | Symbiotec Pharmalab |
|---|---|---|
| NSE Symbol | SUPRIYA | SYMBIOTEC |
| BSE Code | 543434 | 544889 |
| Share Price | ₹628.10 | ₹1,546.20 |
| Market Cap | ₹6,746 Cr | ₹7,871 Cr |
| P/E Ratio | 32.3 | 64.5 |
| Return on Equity | 19.06% | — |
| Return on Assets | 13.46% | 6.96% |
| Dividend Yield | 0.12% | — |
| Beta (1Y) | 0.58 | -3.22 |
| 1-Year Price Change | -19.2% | — |
| 3-Month Price Change | -31.9% | — |
| 52-Week Range | ₹545.50 – ₹1,085.00 | ₹934.20 – ₹1,609.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹206 Cr | ₹280 Cr |
| Quarterly Net Profit | ₹29 Cr | ₹52 Cr |
| Net Margin | 14.2% | 18.5% |
| EPS (Basic, Quarter) | ₹3.63 | ₹8.20 |
| Results Basis | standalone | consolidated |
| Headquarters | Mumbai, Maharashtra | Indore, Madhya Pradesh |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depres…
Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms. The company synthesizes progestin, estrone, testosterone, their derivatives, and anabolic steroids, supplying these in commercial volumes globally. It offers APIs and intermediate pharmaceutical products for therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, paediatrics, anti-infective, and dermatology. The company provides contract manufact…
Symbiotec Pharmalab has a market capitalisation of ₹7,871 Cr, against ₹6,746 Cr for Supriya Lifescience as of 9 Nov 2026, about 1.2 times the size by market cap.
Supriya Lifescience has a P/E of 32.3 and Symbiotec Pharmalab a P/E of 64.5 as of 9 Nov 2026.
Supriya Lifescience reported revenue of ₹206 Cr and net profit of ₹29 Cr for Q2 FY27. Symbiotec Pharmalab reported revenue of ₹280 Cr and net profit of ₹52 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.